These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 18535878)
1. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878 [TBL] [Abstract][Full Text] [Related]
2. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer? Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912 [TBL] [Abstract][Full Text] [Related]
4. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Brink I; Schumacher T; Mix M; Ruhland S; Stoelben E; Digel W; Henke M; Ghanem N; Moser E; Nitzsche EU Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1614-20. PubMed ID: 15258700 [TBL] [Abstract][Full Text] [Related]
5. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial. Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920 [TBL] [Abstract][Full Text] [Related]
6. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027 [TBL] [Abstract][Full Text] [Related]
7. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Lee JW; Lee SM; Lee HS; Kim YH; Bae WK Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551 [TBL] [Abstract][Full Text] [Related]
8. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma. Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268 [TBL] [Abstract][Full Text] [Related]
12. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Aquino SL; Fischman AJ Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753 [TBL] [Abstract][Full Text] [Related]
13. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients. Lim CH; Ahn TR; Moon SH; Cho YS; Choi JY; Kim BT; Lee KH Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418 [TBL] [Abstract][Full Text] [Related]
14. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer]. Guan Y; He S; Dong J Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705 [TBL] [Abstract][Full Text] [Related]
15. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Shen YY; Shiau YC; Wang JJ; Ho ST; Kao CH Anticancer Res; 2002; 22(2B):1257-64. PubMed ID: 12168935 [TBL] [Abstract][Full Text] [Related]
16. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer. Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. Chung JH; Cho KJ; Lee SS; Baek HJ; Park JH; Cheon GJ; Choi CW; Lim SM J Nucl Med; 2004 Jun; 45(6):999-1003. PubMed ID: 15181136 [TBL] [Abstract][Full Text] [Related]
18. Incidence of Brain Metastases on Follow-up Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786 [TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events. Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Koizumi T; Oguchi K Thorac Cancer; 2019 Apr; 10(4):980-987. PubMed ID: 30883012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]